Health Condition 1: D701- Agranulocytosis secondary to cancer chemotherapy Health Condition 2: R509- Fever, unspecified Health Condition 3: D709- Neutropenia, unspecified
Conditions
Interventions
Intervention1: NA: NA
Control Intervention1: NA: NA
Sponsors
Tata Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: a. Subjects with all age group will be included for the study. b. Receiving chemotherapy for newly diagnosed or relapsed malignancy. c. Febrile neutropenia defined as fever (temperature >100.4 F on two occasions within a 12 hour period or 101°F once) during neutropenia (absolute neutrophil count
Exclusion criteria
Exclusion criteria: a. Non-chemotherapy related febrile neutropenia. b. Fever due to underlying malignancy c. Non neutropenic fever
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the outcomes of febrile neutropenia viz resolution of fever, progression to hemodynamic instability, ICU transfer and death.Timepoint: From the time of enrollment till resolution of the febrile neutropenia episode or death of the patient, whichever earlier. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To evaluate the incidence of MDR organism (Details in Appendix-2) 2. To evaluate baseline prognostic factors for outcome. 3. To evaluate patterns of care (escalation or de-escalation) and outcome. 4. To evaluate success to antibiotics and delay in chemotherapy. Timepoint: Daily monitoring of from the enrollment, till recovery from infection, fever and/or neutropenia whichever happens earlier | — |
Countries
India
Contacts
Public ContactDr Lingaraj Nayak
Tata Memorial Hospital
Outcome results
None listed